연구성과로 돌아가기

2021 연구자 정보 (138 / 1146)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Lee, Joo Myung
(Lee, JM)
Sungkyunkwan Univ, Samsung Med Ctr, Heart Vasc Stroke Inst, Dept Internal Med,Sch Med,Div Cardiol, 81 Irwon Ro, Seoul 06351, South Korea J-5597-2012
Lee, Jae

[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention SCIE 4.8 CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp;
Lee, Kwan Sik
(Lee, KS)
Yonsei Univ, Coll Med, Gangnam Severance Hosp, Seoul, South Korea
Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea
D-5883-2012
Lee, Shin-Jae
0000-0002-3672-1198
Lee, Kwan Sik
[JCR상위 4.8] Safety, efficacy, and pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study
[JCR상위 19.9] Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY jenny.yang@gilead.com;
umsh@korea.ac.kr;
Lee, Seung Hun
(Lee, SH)
제1저자 Chonnam Natl Univ Hosp, Dept Cardiol, 42 Jaebong Ro, Gwangju 61469, South Korea
Sungkyunkwan Univ, Samsung Med Ctr, Heart Vasc Stroke Inst, Dept Internal Med,Sch Med,Div Cardiol, 81 Irwon Ro, Seoul 06351, South Korea
AAW-6430-2021
Lee, Seung
0000-0002-2337-7826
Lee, Seung Hun
[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention SCIE 4.8 CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp;
Lee, Yu Rim
(Lee, YR)
Kyungpook Natl Univ, Dept Internal Med, Daegu, South Korea
Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, 130 Dongdeok Ro, Daegu 41944, South Korea
Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea
Kyungpook Natl Univ Hosp, Dept Internal Med, Korea, South Korea
Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea
Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea
Kyungpook Natl Univ, Sch Med, Internal Med, Daegu, South Korea
Kyungpook Natl Univ, Sch Med, Kyungpook Natl Univ Hosp, Dept Internal Med, 130 Dongdeok Ro, Daegu 41944, South Korea
ITU-1407-2023
Lee, YuRim

[JCR상위 4.8] An episode of detectable serum hepatitis B virus-DNA level does not affect risk of hepatic decompensation among untreated compensated cirrhosis patient with viral load of <2, 000 IU/ml
[JCR상위 25.9] Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases
Management of Patients with Chronic Liver Disease: The Era of the COVID-19 Pandemic
[JCR상위 27.6] Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
[JCR상위 71.2] Long interspersed nuclear element-1 hypomethylation is associated with poor outcomes via the activation of ST18 in human hepatocellular carcinoma
[JCR상위 5.9] CIRCULAR NONCODING RNA HSACIRC₀₀₀₅₉₈₆ AS A PROGNOSTIC BIOMARKER FOR HEPATOCELLULAR CARCINOMA
[JCR상위 5.9] CIRCULATING EXOSOMAL LNCRNA-ATB PROMOTES MYOPENIA IN HUMAN HEPATOCELLULAR CARCINOMA
[JCR상위 25.0] Circular noncoding RNA hsacᵢᵣc₀₀₀₅₉₈₆ as a prognostic biomarker for hepatocellular carcinoma
[JCR상위 46.8] Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment
[JCR상위 59.7] Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
[JCR상위 1.3] Deep metric learning-based image retrieval system for chest radiograph and its clinical applications in COVID-19
[JCR상위 32.0] A multi-center study of COVID-19 patient prognosis using deep learning-based CT image analysis and electronic health records
[JCR상위 0.2] Federated learning for predicting clinical outcomes in patients with COVID-19
SCIE 0.2 GASTROENTEROLOGY & HEPATOLOGY
MEDICAL LABORATORY TECHNOLOGY
MEDICINE, GENERAL & INTERNAL
MULTIDISCIPLINARY SCIENCES
GASTROENTEROLOGY & HEPATOLOGY;INFECTIOUS DISEASES;VIROLOGY
COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE;COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS;ENGINEERING, BIOMEDICAL;RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
BIOCHEMISTRY & MOLECULAR BIOLOGY;CELL BIOLOGY;MEDICINE, RESEARCH & EXPERIMENTAL
beomkkim@yuhs.ac;
wytak@knu.ac.kr;
deblue00@naver.com;
ksukorea@yuhs.ac;
KeunHur@knu.ac.kr;
magnolia1103@naver.com;KeunHur@knu.ac.kr;
chung50@dsmc.or.kr;kbs9225@cu.ac.kr;
KSUKOREA@yuhs.ac;
li.quanzheng@mgh.harvard.edu;
MKALRA@mgh.harvard.edu;Li.Quanzheng@mgh.harvard.edu;
mflores@nvidia.com;
Lee, Yun Bin
(Lee, YB)
Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea
Seoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea
Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
Seoul Natl Univ, Coll Med, Liver Res Inst, Seoul, South Korea
AAB-9799-2022
Lee, Yoojin

[JCR상위 4.8] The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts
[JCR상위 5.9] IMPACT OF HBEAG ON HEPATOCELLULAR CARCINOMA RISK DURING ORAL ANTIVIRAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B
SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY pindra@empal.com;
Leung, Daniel Hao Bin
(Leung, DHB)
Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA

[JCR상위 4.8] Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Children with Chronic Hepatitis B (CHB): Final Results from a Placebo-Controlled Trial SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY john.flaherty@gilead.com;
Levy, Cynthia
(Levy, C)
Univ Miami, Miami, FL USA

[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY ychoi@cymabay.com;
Liu, Yang
(Liu, Y)
Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[JCR상위 4.8] Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Children with Chronic Hepatitis B (CHB): Final Results from a Placebo-Controlled Trial SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY john.flaherty@gilead.com;
Mak, Lung Yi Loey
(Mak, LYL)
Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China ABB-1599-2020
Mak, Lung Yi (Loey)

[JCR상위 4.8] ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY jhamilton@arrowheadpharma.com;
Manolakopoulos, Spilios
(Manolakopoulos, S)
Natl & Kapodistrian Univ Athens, Gen Hosp Athens Hippokratio, Dept Internal Med 2, Sch Med, Athens, Greece
Natl & Kapodistrian Univ Athens, Sch Med, Gen Hosp Athens Laiko, Dept Gastroenterol, Athens, Greece
AAD-7058-2019
Manolakopoulos, Spilios

[JCR상위 4.8] The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts
[JCR상위 5.9] IMPACT OF HBEAG ON HEPATOCELLULAR CARCINOMA RISK DURING ORAL ANTIVIRAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B
SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY pindra@empal.com;
Mayo, Marlyn J.
(Mayo, MJ)
Univ Texas Southwestern, Dallas, TX USA

[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY ychoi@cymabay.com;
McDonald, Circe
(McDonald, C)
Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[JCR상위 4.8] Safety, efficacy, and pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY jenny.yang@gilead.com;
McWherter, Charles
(McWherter, C)
CymaBay Therapeut, Newark, CA USA

[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY ychoi@cymabay.com;
Mehta, Rajiv
(Mehta, R)
Surat Inst Med Sci SIDS, Surat, India

[JCR상위 4.8] Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Children with Chronic Hepatitis B (CHB): Final Results from a Placebo-Controlled Trial SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY john.flaherty@gilead.com;
Michael, Galambos
(Michael, G)
Digest Healthcare Georgia, Atlanta, GA USA

[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY ychoi@cymabay.com;
페이지 이동: